These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24668429)

  • 1. [Coronary stents: what is new?].
    Zeus T; Münzel T
    Dtsch Med Wochenschr; 2014 Apr; 139(14):701-3. PubMed ID: 24668429
    [No Abstract]   [Full Text] [Related]  

  • 2. Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation.
    Indolfi C; Mongiardo A; Spaccarotella C; Caiazzo G; Torella D; De Rosa S
    Circ Cardiovasc Imaging; 2014 Jul; 7(4):755-7. PubMed ID: 25027457
    [No Abstract]   [Full Text] [Related]  

  • 3. Restenosis of Coronary Bioresorbable Vascular Scaffolds.
    Alfonso F; García-Guimaraes M
    Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):527-531. PubMed ID: 28285939
    [No Abstract]   [Full Text] [Related]  

  • 4. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy.
    Wykrzykowska JJ; Onuma Y; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F7-8. PubMed ID: 22100680
    [No Abstract]   [Full Text] [Related]  

  • 5. Optical Coherence Tomography of Magnesium Bioresorbable Scaffold Restenosis.
    García-Blas S; Miñana G; Sanchis J
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1069. PubMed ID: 29223376
    [No Abstract]   [Full Text] [Related]  

  • 6. A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds.
    Waksman R
    Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e20-e24. PubMed ID: 29281608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioresorbable Stents in PCI.
    Lindholm D; James S
    Curr Cardiol Rep; 2016 Aug; 18(8):74. PubMed ID: 27312934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable vascular scaffolds: implication of very late scaffold thrombosis.
    Mori H; Virmani R; Finn AV
    Coron Artery Dis; 2017 Nov; 28(7):533-538. PubMed ID: 28692483
    [No Abstract]   [Full Text] [Related]  

  • 10. Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?
    Bangalore S; Mauri L
    EuroIntervention; 2009 Dec; 5 Suppl F():F43-8. PubMed ID: 22100675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism.
    Cassese S; Kastrati A
    J Am Coll Cardiol; 2016 Mar; 67(8):932-935. PubMed ID: 26916482
    [No Abstract]   [Full Text] [Related]  

  • 12. Pitfalls of bioresorbable vascular scaffold thrombosis--be sure to cover it all.
    Abu Sharar H; Katus HA; Bekeredjian R
    Int J Cardiol; 2014 Dec; 177(3):1067-8. PubMed ID: 25465842
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of post-dilatation on strut apposition of second-generation bioresorbable vascular scaffolds: Key role for scaffold thrombosis and prognosis?
    Frangieh AH; Jaguszewski M; Imori Y; Obeid S; Templin C
    Cardiol J; 2018; 25(1):148-150. PubMed ID: 29512102
    [No Abstract]   [Full Text] [Related]  

  • 14. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone-eluting vascular stents.
    Hämäläinen M; Nieminen R; Uurto I; Salenius JP; Kellomäki M; Mikkonen J; Kotsar A; Isotalo T; Teuvo Tammela LJ; Talja M; Moilanen E
    Basic Clin Pharmacol Toxicol; 2013 May; 112(5):296-301. PubMed ID: 23374962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late structural discontinuity and migration of a bioabsorbable scaffold in a saphenous vein graft].
    Sganzerla P; Tavasci E
    G Ital Cardiol (Rome); 2016 Mar; 17(3):237-40. PubMed ID: 27029883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biosoluble coronary stents].
    Gerasimov AM; Mironov VM; Samko AN; Merkulov EV; Davydov DP
    Vestn Rentgenol Radiol; 2013; (3):55-60. PubMed ID: 25669078
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioresorbable vascular scaffolds in coronary bifurcation lesions: The next frontiers?
    Leesar MA
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):870-871. PubMed ID: 27886452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.